Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Glioblastoma 4Brain Neoplasms 4Neuroblastoma 3Medulloblastoma 2Recurrence 1Neoplasm Metastasis 1Gliosarcoma 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Temozolomide 23Bevacizumab 18Cyclophosphamide 9Carboplatin 7Lomustine 6Irinotecan 63-Iodobenzylguanidine 6Topotecan 5Radiotherapy 5Filgrastim 5Radiosurgery 4Nivolumab 4Everolimus 4Etoposide 4Drug Therapy 4Busulfan 4sonidegib 3pembrolizumab 3olaparib 3fludarabine phosphate 3fludarabine 3cemiplimab 3antineoplaston AS 2-1 3antineoplaston A10 3Vincristine 3Thiotepa 3Sirolimus 3Melphalan 3IL13-PE38 3Antilymphocyte Serum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × TPI-287 × CNS × Clear all
NCT00867568 2024-08-06

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Milton S. Hershey Medical Center

Phase 1 Completed
18 enrolled 12 charts
CNS

Medulloblastoma, Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡